Anavex Life Sciences Corp. (AVXL) stock
AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.72−0.02 (-2.78%)
Close on Nov 18, 2026Market cap $66.69MP/E –Yield –
Anavex Life Sciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Anavex Life Sciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$29.29M. For fiscal 2025 it was -$39.04M. The highest annual figure on record is -$777.57K in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$39.04M | – |
| FY2024 | Sep 30, 2024 | -$30.81M | – |
| FY2023 | Sep 30, 2023 | -$27.79M | – |
| FY2022 | Sep 30, 2022 | -$24.24M | – |
| FY2021 | Sep 30, 2021 | -$30.38M | – |
| FY2020 | Sep 30, 2020 | -$21.29M | – |
| FY2019 | Sep 30, 2019 | -$18.53M | – |
| FY2018 | Sep 30, 2018 | -$12.58M | – |
| FY2017 | Sep 30, 2017 | -$9.02M | – |
| FY2016 | Sep 30, 2016 | -$9.24M | – |
| FY2015 | Sep 30, 2015 | -$4.23M | – |
| FY2014 | Sep 30, 2014 | -$2.66M | – |
| FY2013 | Sep 30, 2013 | -$777.57K | – |
| FY2012 | Sep 30, 2012 | -$1.69M | – |
| FY2011 | Sep 30, 2011 | -$3.80M | – |
| FY2010 | Sep 30, 2010 | -$4.59M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$9.10M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$4.44M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$7.15M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$8.60M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$12.46M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$5.86M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$12.12M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$6.66M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$5.18M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$11.66M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$7.32M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$5.85M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$7.65M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$8.49M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$5.79M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$4.04M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$7.05M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$9.64M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$3.50M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$7.67M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$7.52M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$7.32M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$7.87M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$6.25M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$4.04M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$5.26M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$5.73M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$2.53M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$7.50M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$4.33M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$4.16M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$4.05M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$2.09M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$2.82M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$3.62M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$2.19M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$2.97M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$697.74K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$3.15M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$1.86M | – |
See a number that looks wrong?